OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Hold” by Analysts

Posted by Brenda Bartman on Aug 14th, 2026

Shares of OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) have been given an average rating of “Hold” by the five research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $1.55.

Several research firms recently commented on OPK. Weiss Ratings upgraded shares of OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Barrington Research downgraded shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 29th. Finally, HC Wainwright reissued a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th.

Check Out Our Latest Report on OPK

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.40 on Friday. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.73. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The stock has a market cap of $1.04 billion, a PE ratio of -15.56 and a beta of 1.51. The business has a fifty day simple moving average of $1.38 and a 200-day simple moving average of $1.27.

OPKO Health (NASDAQ:OPK – Get Free Report) last posted its quarterly earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. During the same period in the previous year, the firm earned ($0.19) earnings per share. OPKO Health’s quarterly revenue was up 4.3% on a year-over-year basis. On average, sell-side analysts anticipate that OPKO Health will post -0.24 EPS for the current fiscal year.

Institutional Trading of OPKO Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Zacks Investment Management acquired a new stake in OPKO Health during the fourth quarter valued at $27,000. StoneX Group Inc. acquired a new position in OPKO Health in the 4th quarter worth about $27,000. Great Lakes Advisors LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth about $1,145,000. Apella Capital LLC purchased a new stake in shares of OPKO Health during the 1st quarter worth about $34,000. Finally, Cibc World Markets Corp acquired a new stake in shares of OPKO Health during the 4th quarter valued at about $34,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Company Profile

(Get Free Report)

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.